Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Citadel Group has disclosed a 1.33% interest in Mural Oncology plc, according to a regulatory filing published Monday.
The position disclosure, made under Irish Takeover Panel rules, shows Citadel holds 230,628 shares representing 1.33% of the biopharmaceutical company, alongside a short position of 1.11% as of October 3, 2025.
The filing details that Citadel directly owns 217,228 common shares, equivalent to 1.25% of Mural Oncology, with additional exposure through stock-settled derivatives representing 0.07% of the company.
The disclosure also reveals multiple transactions conducted by Citadel on October 3, including purchases of Mural Oncology shares at prices ranging from $2.07 to $2.09 per share, alongside corresponding sales at similar price points.
The options positions disclosed include put and call options with various strike prices between $2.50 and $7.50, with expiration dates extending from October 2025 to January 2027.
Irish Takeover Panel rules require disclosure of positions representing 1% or more of a company’s securities during offer periods.
Mural Oncology, listed on the Irish Stock Exchange, focuses on developing cancer therapeutics. The company’s shares closed at $2.09 on Friday.
The information was disclosed in a Form 8.3 filing submitted to the Regulatory Information Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.